Saudi Journal of Gastroenterology
Home About us Instructions Submission Subscribe Advertise Contact Login    Print this page  Email this page Small font sizeDefault font sizeIncrease font size 
Users Online: 301 
NEW HORIZON
Year : 2009  |  Volume : 15  |  Issue : 3  |  Page : 208-212

Growth factors as treatment for inflammatory bowel disease: A concise review of the evidence toward their potential clinical utility


1 Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City; Universidad Nacional Autónoma de México, Mexico City, Mexico; Instituto de Enfermedades Digestivas y Nutricionales, Guatemala City, Guatemala
2 Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City
3 Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City; Universidad Nacional Autónoma de México, Mexico City, Mexico

Correspondence Address:
Josue Barahona-Garrido
Avenida Reforma 7-62 zona 9, Edificio Aristos Reforma, Oficina 109, Guatemala City, Guatemala, CP 01009

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/1319-3767.54742

Rights and Permissions

In the process of inflammation and repair of the intestinal mucosa in inflammatory bowel disease (IBD), there occurs a complex and an unknown interplay of innate and adaptive immune mechanisms. This interaction of factors may explain why IBD is characterized by a relapsing and remitting clinical course. Different components of innate immunity, hormones and interleukins in IBD have been suggested to be impaired. The growth hormone, epidermal growth factor, keratinocyte growth factor and colony-stimulating factors have emerged as potential tools for the modulation of intestinal inflammation and repair. Despite promising results of initial studies, the evidence that justify treatment of patients in clinical practice is not enough as some of the trials are nonrandomized or included a small number of patients. In this concise review, we provide a summary of the most recent and relevant evidence regarding the potential therapeutic effects of growth factors in IBD.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed4146    
    Printed135    
    Emailed1    
    PDF Downloaded712    
    Comments [Add]    
    Cited by others 1    

Recommend this journal